Aura Biosciences (AURA) Return on Capital Employed (2021 - 2026)
Aura Biosciences' (AURA) quarterly Return on Capital Employed came in at 86.68% in Q1 2026, down 2109.0% YoY from 4.31% in Q1 2025, and down 24.0% on a QoQ basis from 69.91% in Q4 2025.
Aura Biosciences (AURA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 6 years of Return on Capital Employed data on file, last reported at 86.68% in Q1 2026.
- Quarterly Return on Capital Employed fell 2109.0% year-over-year to 86.68% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 86.68% (down 2109.0% YoY) and the FY2025 annual result came in at 71.58%, down 2443.0% from the prior year.
- Return on Capital Employed slipped to 86.68% in Q1 2026, from 69.91% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 28.43% in Q1 2022 to a low of 86.68% in Q1 2026.
- A 5-year average of 48.74% and a median of 42.06% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed sank 232 bps — and 2025, when it slumped 2826 bps.
- Tracing AURA's Return on Capital Employed over 5 years: stood at 34.84% in 2022, then decreased by 19 bps to 41.45% in 2023, then decreased by 30 bps to 53.69% in 2024, then plunged by 30 bps to 69.91% in 2025, then declined by 24 bps to 86.68% in 2026.
- The last three Return on Capital Employed figures came in at 86.68% (Q1 2026), 69.91% (Q4 2025), and 63.55% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | -61.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.82% |
| Mar 31, 2026 | -86.68% |
| Dec 31, 2025 | -69.91% |
| Sep 30, 2025 | -63.55% |
| Jun 30, 2025 | -65.85% |
| Mar 31, 2025 | -65.59% |
| Dec 31, 2024 | -53.69% |
| Sep 30, 2024 | -47.23% |
| Jun 30, 2024 | -41.81% |
| Mar 31, 2024 | -37.33% |
| Dec 31, 2023 | -41.45% |
| Sep 30, 2023 | -44.38% |
| Jun 30, 2023 | -38.53% |
| Mar 31, 2023 | -32.35% |
| Dec 31, 2022 | -34.84% |
| Sep 30, 2022 | -42.06% |
| Jun 30, 2022 | -34.95% |
| Mar 31, 2022 | -28.43% |
| Dec 31, 2021 | -29.87% |